



RhoVac's co-founder Anders Ljungqvist has passed away

It is with great sadness that we have received the news that Anders Ljungqvist, co-founder of RhoVac has passed away after a period of illness.

Anders was the co-founder of RhoVac ApS in 2007 and CEO for several years including the listing of RhoVac AB in Stockholm in 2016. In the later years he moved to the board of directors but was still close to the operations with his long experience from drug development.

During the autumn of 2022 his illness worsened, and he was forced to leave the board to focus on his health and family. However even after this we were looking to him for advice when this was possible.

Anders was a person of great integrity and competence, always looking for constructive solutions to problems facing the company. He was great person to have as a colleague, manager and fellow board member and he will be duly missed by us all. Our thoughts today are with his wife Lene and his family.

The funeral will take place in Rungsted Kirke on December 28th at 11:00 AM

Gunnar Gårdemyr
Chairman

Lars Hedbys
Acting CEO

For information, please contact:

Lars Hedbys – CEO, RhoVac AB
Phone: +46 73 751 7278
E-mail: info@rhovac.com

On RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has passed the early stages of development. In 2019, patient recruitment began for a larger clinical phase IIb study that included more than 180 patients with prostate cancer. The Top Line results were presented in May 2022. Further data are currently being evaluated. RhoVac is listed on the Spotlight Stockmarket. The share is traded under the ticker RHOVAC. More information is available at www.rhovac.com.